Activation of the Proapoptotic Death Receptor DR5 by Oligomeric Peptide and Antibody Agonists

Journal of Molecular Biology

Volumn 361, Issue 3, 2006, Pages 522-536

  Li, Bing ^a   Russell, Stephen J ^a   Compaan, Deanne M ^a   Totpal, Klara ^a   Marsters, Scot A ^a   Ashkenazi, Avi ^a   Cochran, Andrea G ^a   Hymowitz, Sarah G ^a   Sidhu, Sachdev S ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody library; apoptosis; peptide library; phage display; protein engineering

Indexed keywords

ANTIBODY; ASPARAGINYLVALYLASPARTYLGLUTAMINYLGLUTAMYLCYSTEINYLMETHIONYLTHREONYL THREONYLCYSTEINYLTHREONYLARGINYLLEUCYLARGINYLGLUTAMYLCYSTEINYLGLUTAMINYLLEUCYL LEUCINE; DEATH RECEPTOR 5; DEATH RECEPTOR 5 ANTIBODY; GLUTAMINYLGLUTAMYLVALYLCYSTEINYLMETHIONYLTHREONYLSERYLCYSTEINYLASPARTYL LYSYLLEUCYLMETHIONYLLYSYLCYSTEINYLASPARAGINYLTRYPTOPHANYLMETHIONYLALANYLALANYL ASPARAGINE; GLUTAMYLVALYLCYSTEINYLMETHIONYLTHREONYLSERYLCYSTEINYLGLUTAMYLLYSYLLEUCYL METHIONYLALANYLLEUCYLSERYLLEUCINE; GLYCYLARGINYLVALYLCYSTEINYLLEUCYLTHREONYLLEUCYLCYSTEINYLSERYLARGINYLLEUCYL THREONINE; GLYCYLARGINYLVALYLCYSTEINYLLEUCYLTHREONYLLEUCYLCYSTEINYLSERYLLYSYLLEUCYL ARGININE; GLYCYLARGINYLVALYLCYSTEINYLLEUCYLTHREONYLLEUCYLCYSTEINYLSERYLLYSYLLEUCYL THREONINE; GLYCYLGLUTAMYLVALYLCYSTEINYLLEUCYLTHREONYLLEUCYLCYSTEINYLSERYLARGINYL LEUCYLTHREONINE; GLYCYLGLUTAMYLVALYLCYSTEINYLLEUCYLTHREONYLLYSYLCYSTEINYLSERYLLYSYLLEUCYL THREONINE; GLYCYLGLUTAMYLVALYLCYSTEINYLLEUCYLTHREONYLSERYLCYSTEINYLGLUTAMYLARGINYL LEUCYLARGININE; GLYCYLGLUTAMYLVALYLCYSTEINYLLEUCYLTHREONYLSERYLCYSTEINYLSERYLARGINYLLEUCYL ARGININE; OLIGOMER; PEPTIDE; TRIPEPTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL DEATH; CELL SURFACE; CRYSTAL STRUCTURE; HOMEOSTASIS; LUNG CARCINOMA; METAZOON; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TUMOR CELL; X RAY CRYSTALLOGRAPHY;

METAZOA;

EID: 33746694185     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.06.042     Document Type: Article

References (62)

1. Jacobsen M.D., Weil M., and Raff M.C. Programmed cell death in animal development. Cell 88 (1997) 347-354
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2 (2002) 420-430
3. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 (2003) 17-22
4. Adams J., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998) 1322-1326
5. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
6. Green D. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000) 1-4
7. Hunt A., and Evan G. Till death us do part. Science 293 (2001) 1784-1785
8. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
9. Acehan D., Jiang X., Morgan D.G., Heuser J.E., Wang X., and Akey C.W. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding and activation. Mol. Cell. 9 (2002) 423-432
10. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
11. Schmitt C.A. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nature Rev. Cancer 3 (2003) 286-295
12. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
13. Denicourt C., and Dowdy S.F. Targeting apoptotic pathways in cancer cells. Science 305 (2004) 1411-1413
14. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
15. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5 (1999) 157-163
16. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
17. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.-P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
18. Mariani S.M., Matiba B., Armandola E.A., and Krammer P.H. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell Biol. 137 (1997) 221-229
19. Pan G., Ni J., Wei Y.-F., Yu G.-L., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
20. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
21. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
22. Walczak H., Degli-Esposito M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (1997) 5386-5397
23. Delgi-Esposito M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
24. Delgi-Esposito M.A., Smolak P.J., Walczak H., Waugh J., Huang C.-P., Dubose R.F., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186 (1997) 1165-1170
25. Emery J.G., McDonnell P., Brigham Burke M., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
26. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
27. Cha S.-S., Kim M.-S., Choi Y.H., Sung B.-J., Shin N.K., Shin H.-C., et al. 2.8 Å resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11 (1999) 253-261
28. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 (2000) 633-640
29. Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M., Kelley R.F., et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell. 4 (1999) 563-571
30. Cha S.-S., Sung B.-J., Kim Y.-A., Song Y.-L., Kim H.-J., Kim S., et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275 (2000) 31171-31177
31. Mongkolsapaya J., Grimes J.M., Chen N., Xu X.-N., Stuart D.I., Jones E.Y., and Screaton G.R. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nature Struct. Biol. 6 (1999) 1048-1053
32. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., DeForge L., et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280 (2005) 2205-2212
33. Chuntharapai A., Dodge K., Grimmer K., Schroeder K., Marsters S.A., Koeppen H., et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166 (2001) 4891-4898
34. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162 (1999) 2597-2605
35. Ichikawa K., Liu W., Zhao L., Zheng W., Liu D., Ohtsuka T., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7 (2001) 954-960
36. Eigenbrot C., Randal M., Presta L., Carter P., and Kossiakoff A.A. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. 229 (1993) 969-995
37. Fellouse F.A., Wiesmann C., and Sidhu S.S. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc. Natl Acad. Sci. USA 101 (2004) 12467-12472
38. Fellouse F.A., Bing L., Compaan D.M., Peden A.A., Hymowitz S.G., and Sidhu S.S. Molecular recognition by a binary code. J. Mol. Biol. 348 (2005) 1153-1162
39. Sidhu S.S. Phage display in pharmaceutical biotechnology. [Review] [51 refs]. Curr. Opin. Biotechnol. 11 (2000) 610-616
40. Sidhu S.S., Fairbrother W.J., and Deshayes K. Exploring protein-protein interactions with phage display. ChemBioChem 4 (2003) 14-25
41. Sidhu S.S., Lowman H.B., Cunningham B.C., and Wells J.A. Phage display for selection of novel binding peptides. Methods Enzymol. 328 (2000) 333-363
42. Lee C.V., Liang W.-C., Dennis M.S., Eigenbrot C., Sidhu S.S., and Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 340 (2004) 1073-1093
43. Sidhu S.S., Li B., Chen Y., Fellouse F.A., Eigenbrot C., and Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J. Mol. Biol. 338 (2004) 299-310
44. Lee C.V., Sidhu S.S., and Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. J. Immunol. Methods 284 (2004) 119-132
45. Harbury P.B., Zhang T., Kim P.S., and Alber T. A switch between two-, three- and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262 (1993) 1401-1407
46. Zwick M.B., Bonnycastle L.L., Menendez A., Irving M.B., Barbas C.F.r., Parren P.W., et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J. Virol. 75 (2001) 6692-6699
47. Georgakis G.V., Li Y., Humphreys R., Andreeff M., O'Brien S., Younes M., et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol. 130 (2005) 501-510
48. Pukac L., Kanakaraj P., Humphreys R., Alderson R., Bloom M., Sung C., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br.. J. Cancer 92 (2005) 1430-1441
49. 3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nature Chem. Biol. 1 (2005) 377-382
50. Delano W.L., Ultsch M.H., de Vos A.M., and Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 287 (2000) 1279-1283
51. Chan F.K.-M., Chun H.J., Zheng L., Siegel R.M., Bui K.L., and Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288 (2000) 2351-2354
52. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K.-M., Johnson M., Lynch D., et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288 (2000) 2354-2357
53. Clancy L., Mruk K., Archer K., Woelfel M., Mongkolsapaya J., Screaton G., et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-incuded apoptosis. Proc. Natl Acad. Sci. USA 102 (2005) 18099-18104
54. Deshayes K., Schaffer M.L., Skelton N.J., Nakamura G.R., Kadkhodayan S., and Sidhu S.S. Rapid identification of small binding motifs with high-throughput phage display: discovery of peptidic antagonists of IGF-1 function. Chem. Biol. 9 (2002) 495-505
55. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
56. Eaton D.L., Wood W.I., Eaton D., Hass P.E., Hollingshead P., Wion K., et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25 (1986) 8343-8347
57. Miller K., Meng G., Liu J., Hurst A., Hsei V., Wong W.-L., et al. Design, construction, and in vitro analyses of multivalent antibodies. J. Immunol. 170 (2003) 4854-4861
58. Gorman C.M., Gies D.R., and McCray G. Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng. Techniq. 2 (1990) 1-28
59. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., and de Vos A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6 (1998) 1153-1167
60. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallog. Pt A 276 (1997) 307-326
61. CCP4. The CCP4 suite: Programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
62. Kabat E.A., Wu T.T., Redi-Miller M., Perry H.M., and Gottesman K.S. Sequences of Proteins of Immunological Interest. 4th edit (1987), National Institutes of Health, Bethesda, MD